MX359638B - Vacunas basadas en el virus de la parainfluenza 5. - Google Patents

Vacunas basadas en el virus de la parainfluenza 5.

Info

Publication number
MX359638B
MX359638B MX2014008557A MX2014008557A MX359638B MX 359638 B MX359638 B MX 359638B MX 2014008557 A MX2014008557 A MX 2014008557A MX 2014008557 A MX2014008557 A MX 2014008557A MX 359638 B MX359638 B MX 359638B
Authority
MX
Mexico
Prior art keywords
gene
nucleotide sequence
genome
parainfluenza virus
heterologous nucleotide
Prior art date
Application number
MX2014008557A
Other languages
English (en)
Spanish (es)
Other versions
MX2014008557A (es
Inventor
He Biao
Original Assignee
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia filed Critical Univ Georgia
Publication of MX2014008557A publication Critical patent/MX2014008557A/es
Publication of MX359638B publication Critical patent/MX359638B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18732—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18771—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2014008557A 2012-01-24 2013-01-24 Vacunas basadas en el virus de la parainfluenza 5. MX359638B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261590056P 2012-01-24 2012-01-24
US201261590070P 2012-01-24 2012-01-24
US201261683810P 2012-08-16 2012-08-16
PCT/US2013/022962 WO2013112720A1 (en) 2012-01-24 2013-01-24 Parainfluenza virus 5 based vaccines

Publications (2)

Publication Number Publication Date
MX2014008557A MX2014008557A (es) 2014-10-24
MX359638B true MX359638B (es) 2018-10-04

Family

ID=48873896

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008557A MX359638B (es) 2012-01-24 2013-01-24 Vacunas basadas en el virus de la parainfluenza 5.

Country Status (13)

Country Link
US (6) US9505807B2 (enExample)
EP (2) EP2806891B1 (enExample)
JP (3) JP6228136B2 (enExample)
CN (2) CN104093422B (enExample)
AU (1) AU2013212097B2 (enExample)
BR (1) BR112014018179B1 (enExample)
CA (2) CA2860388C (enExample)
ES (1) ES2728248T3 (enExample)
MX (1) MX359638B (enExample)
MY (1) MY173638A (enExample)
PH (1) PH12014501255B1 (enExample)
PT (1) PT2806891T (enExample)
WO (2) WO2013112690A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3123276A1 (en) 2011-02-25 2012-08-30 University Of Georgia Research Foundation, Inc. Recombinant mumps virus vaccine
AU2013212097B2 (en) 2012-01-24 2017-01-12 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines
KR101577397B1 (ko) * 2014-01-15 2015-12-28 경북대학교 산학협력단 신규한 돼지 파라인플루엔자 바이러스 5(pPIV5), 이를 포함하는 백신 조성물 및 이를 이용한 돼지 파라인플루엔자 바이러스 검정 키트
EP3288595B1 (en) * 2015-04-28 2020-12-30 The University Of Georgia Research Foundation, Inc. Piv5-based amplifying virus-like particles
US20180339038A1 (en) * 2015-06-12 2018-11-29 Mie University Human parainfluenza virus type 2 vector and vaccine
IL270876B2 (en) * 2017-05-25 2024-06-01 Univ Central Florida Res Found Inc Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
RU2681473C1 (ru) * 2018-01-16 2019-03-06 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Тест-система для обнаружения генома вируса парагриппа 3 типа у крупного рогатого скота с помощью мультиплексной полимеразной цепной реакции с флуоресцентной детекцией в режиме реального времени
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
WO2020092207A1 (en) * 2018-10-28 2020-05-07 University Of Georgia Research Foundation Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof
CL2018003869A1 (es) * 2018-12-28 2021-01-15 Univ Pontificia Catolica Chile Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv
CA3196157A1 (en) * 2020-09-21 2022-03-24 University Of Georgia Research Foundation, Inc. Piv5-based covid-19 vaccine
US20240102912A1 (en) * 2020-11-09 2024-03-28 Thrive Bioscience, Inc. Plaque counting assay method
CN113005149A (zh) * 2021-03-26 2021-06-22 中国农业大学 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体
AU2022332107A1 (en) * 2021-08-26 2024-03-14 University Of Georgia Research Foundation, Inc. J paramyxovirus vaccines
GB202209861D0 (en) * 2022-07-05 2022-08-17 Univ Court Univ St Andrews Viral vectors
AU2023372210A1 (en) * 2022-11-04 2025-05-29 Blue Lake Biotechnology, Inc. Recombinant rsv vaccine: methods of making and using the same
JP2026504603A (ja) * 2023-02-06 2026-02-05 サイアンバック エルエルシー 修飾ｐｉｖ５ワクチンベクター：作製方法及び使用方法
CN116270766A (zh) * 2023-02-23 2023-06-23 天津理工大学 一种副流感病毒5型作为溶瘤病毒在抗肿瘤中的应用
CN117625560B (zh) * 2023-11-03 2025-09-16 中国农业大学 一种重组病毒rPIV5-H3及其制备方法、应用和疫苗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
CA2160038A1 (en) * 1995-07-14 1997-01-15 Biosignal Inc. Methods of screening compounds for their pharmacological relevance based on downregulation of recombinant receptors
JP2000509280A (ja) 1996-05-01 2000-07-25 アメリカ合衆国 組換えｄｎａ由来ヌクレオキャプシドタンパク質を用いるウイルストランスフェクタントの作製
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US5962274A (en) 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
CN102766605A (zh) * 1999-12-10 2012-11-07 由卫生与公众服务部代表的美利坚合众国政府 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
JP2002153278A (ja) 2000-11-22 2002-05-28 Hisamitsu Pharmaceut Co Inc ウイルスベクターの製造に用いられる細胞、その製法およびその細胞を用いたウイルスベクターの製造方法
AU2002327755A1 (en) 2001-09-28 2003-04-14 Rush-Presbyterian-St. Luke's Medical Center Paramyxoviruses as gene transfer vectors to lung cells
WO2005005645A1 (en) 2003-06-13 2005-01-20 Apath, Llc Negative strand rna virus replicon
DK2540312T3 (en) 2007-07-19 2015-07-20 Novavax Inc Chimeric avian influenza VLPs
US20090208495A1 (en) 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
FR2938840B1 (fr) 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
AU2013212097B2 (en) 2012-01-24 2017-01-12 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines

Also Published As

Publication number Publication date
US10752916B2 (en) 2020-08-25
WO2013112690A1 (en) 2013-08-01
PT2806891T (pt) 2019-07-01
BR112014018179B1 (pt) 2022-04-12
CA2860388A1 (en) 2013-08-01
CA2860388C (en) 2021-10-26
CN104093422A (zh) 2014-10-08
JP6228136B2 (ja) 2017-11-08
CA3128591A1 (en) 2013-08-01
US20190284578A1 (en) 2019-09-19
PH12014501255B1 (en) 2019-10-16
CN108130345A (zh) 2018-06-08
JP2020014470A (ja) 2020-01-30
US20140370050A1 (en) 2014-12-18
EP2806891A1 (en) 2014-12-03
WO2013112720A1 (en) 2013-08-01
US20170067080A1 (en) 2017-03-09
US20150086588A1 (en) 2015-03-26
MX2014008557A (es) 2014-10-24
JP2015506689A (ja) 2015-03-05
EP2806891A4 (en) 2015-08-26
EP3536341A1 (en) 2019-09-11
US9732358B2 (en) 2017-08-15
AU2013212097B2 (en) 2017-01-12
CN104093422B (zh) 2018-02-23
JP2018050624A (ja) 2018-04-05
PH12014501255A1 (en) 2014-09-08
BR112014018179A2 (pt) 2017-07-04
MY173638A (en) 2020-02-12
AU2013212097A1 (en) 2014-06-26
US9505807B2 (en) 2016-11-29
EP2806891B1 (en) 2019-04-10
JP6900437B2 (ja) 2021-07-07
ES2728248T3 (es) 2019-10-23
US11542527B2 (en) 2023-01-03
US20200377908A1 (en) 2020-12-03
US10329585B2 (en) 2019-06-25
US20170327845A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
PH12014501255A1 (en) Parainfluenza virus 5 based vaccines
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
MX2025014318A (es) Vector de adenovirus de chimpance util para la administracion de neoantigenos
WO2019126762A3 (en) Cas12a systems, methods, and compositions for targeted rna base editing
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
PH12018500855A1 (en) Herpes simplex virus vaccine
WO2014152432A3 (en) Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
MX357803B (es) Moléculas de ácido nucleico artificiales.
WO2015200555A3 (en) Rna modification to engineer cas9 activity
MX392639B (es) Vectores virales recombinantes para la integración de transgenes
HK1252144A1 (zh) 提高原代細胞中基於核酸內切酶的基因編輯
MX2016010649A (es) Vector de virus adeno-asociado.
WO2015052543A3 (en) Malaria vaccination
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
WO2007124327A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
EA201691120A1 (ru) Векторные композиции и способы индукции усиленного иммунного ответа с использованием векторов поксвируса
WO2012116253A3 (en) Recombinant mumps virus vaccine
MX2015016765A (es) Celulas aviares para la produccion mejorada de virus.
MX2017006671A (es) Plásmidos y método para obtener partículas virales.
WO2013046216A3 (en) Two plasmid mammalian expression system
MY199945A (en) Vaccines against infectious diseases caused by positive stranded rna viruses
WO2014053910A3 (en) Gall wasp control agents

Legal Events

Date Code Title Description
FG Grant or registration